A Practical Guide to Make Digital Tools Work With GLP-1s
GLP-1 receptor agonists have transformed obesity and type 2 diabetes treatment, but patients often struggle with adherence and management. Many turn to digital tools for support, yet their effectiveness varies significantly. Clinicians emphasize the importance of integrating these tools into care while focusing on meaningful health outcomes rather than superficial metrics.
- ▪65% of patients without type 2 diabetes discontinue GLP-1 therapy within a year, compared to 47% of those with type 2 diabetes.
- ▪Clinicians should prioritize real health outcomes over marketing claims when evaluating digital tools.
- ▪Apps that do not align with current metabolic health paradigms may reinforce unhealthy behaviors.
Opening excerpt (first ~120 words) tap to expand
GLP-1 receptor agonists have reshaped the treatment of obesity and type 2 diabetes, but the prescription is only the starting point. Patients face a steep learning curve around nutrition, side-effect management, and long-term behavior change, and many turn to apps, wearables, and telehealth platforms to fill the gaps between office visits.Real-world persistence tells a tougher story. A 2025 cohort study published in JAMA Network Open found that 65% of patients without type 2 diabetes discontinued GLP-1 therapy within a year compared with 47% among those with type 2 diabetes.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
